Your session is about to expire
← Back to Search
JAK Inhibitor
CTP-543 for Alopecia Areata
Phase 2 & 3
Waitlist Available
Research Sponsored by Concert Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 276 weeks
Awards & highlights
Study Summary
This trial will look at the long-term safety of CTP-543 for hair loss in adults with alopecia areata.
Who is the study for?
This trial is for adults with moderate to severe alopecia areata who have already completed 24 weeks of treatment in a prior CTP-543 study. Participants should not have donated blood recently, must not have active scalp conditions needing topical treatments, and females should not be nursing, pregnant or planning pregnancy during the study and for a month after.Check my eligibility
What is being tested?
The trial is testing the long-term safety and effectiveness of a drug called CTP-543 for treating hair loss caused by alopecia areata. It's an extension study, meaning it continues from previous research on the same medication.See study design
What are the potential side effects?
While specific side effects of CTP-543 aren't listed here, common ones may include reactions at the pill intake site, gastrointestinal symptoms like nausea or diarrhea, headaches, fatigue or allergic reactions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 276 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~276 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Effect of CTP-543 on treating hair loss as measured by the Severity of Alopecia Tool (SALT)
Number of Participants with Adverse Events as a Measure of Safety
Side effects data
From 2022 Phase 3 trial • 706 Patients • NCT0451899512%
Headache
9%
Acne
6%
Blood creatine phosphokinase (increased)
5%
COVID-19
5%
Nasopharyngitis
3%
Upper respiratory tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
CTP-543 8 mg BID
CTP-543 12 mg BID
Trial Design
1Treatment groups
Experimental Treatment
Group I: CTP-543Experimental Treatment1 Intervention
Patients who previously completed a qualifying CTP-543 clinical trial
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CTP-543
2021
Completed Phase 3
~2110
Find a Location
Who is running the clinical trial?
Concert PharmaceuticalsLead Sponsor
34 Previous Clinical Trials
3,411 Total Patients Enrolled
7 Trials studying Alopecia Areata
2,219 Patients Enrolled for Alopecia Areata
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have scalp conditions like psoriasis needing topical treatment, significant scalp trauma, or untreated actinic keratosis.I agree to give blood for the study and 30 days after my last dose.I am not pregnant, nursing, or planning to become pregnant during the study and for 30 days after.
Research Study Groups:
This trial has the following groups:- Group 1: CTP-543
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Alopecia Areata Patient Testimony for trial: Trial Name: NCT03898479 — Phase 2 & 3
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger